Pictet Asset Management
BIO icon

Pictet Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pictet Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$807K Sell
2,750
-170
-6% -$48.2K ﹤0.01% 1241
2026
Q1 		$814K Buy
2,920
+340
+13% +$97.9K ﹤0.01% 1203
2025
Q4 		$782K Buy
2,580
+160
+7% +$49.9K ﹤0.01% 1224
2025
Q3 		$679K Sell
2,420
-340
-12% -$92.5K ﹤0.01% 1237
2025
Q2 		$666K Sell
2,760
-11,572
-81% -$2.74M ﹤0.01% 1233
2025
Q1 		$3.49M Buy
14,332
+1,214
+9% +$365K ﹤0.01% 843
2024
Q4 		$4.31M Buy
13,118
+91
+0.7% +$30.9K ﹤0.01% 833
2024
Q3 		$4.36M Sell
13,027
-1,774
-12% -$563K ﹤0.01% 819
2024
Q2 		$4.04M Buy
14,801
+1,320
+10% +$384K ﹤0.01% 814
2024
Q1 		$4.66M Sell
13,481
-1,138
-8% -$374K 0.01% 795
2023
Q4 		$4.72M Buy
14,619
+4,284
+41% +$1.34M 0.01% 804
2023
Q3 		$3.7M Buy
+10,335
New +$3.99M ﹤0.01% 830

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Pictet Asset Management's BIO Position: Q2 2026 in Review

Pictet Asset Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 5.8% in Q2 2026, selling an estimated $48.2K and leaving 2,750 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

Pictet Asset Management first reported a position in BIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.72M in Q4 2023. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Pictet Asset Management held 2,750 shares of Bio-Rad Laboratories Class A worth $807K as of Q2 2026.
  • Pictet Asset Management sold 170 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $48.2K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1241 holding.
  • Pictet Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Bio-Rad Laboratories Class A position peaked at $4.72M in Q4 2023.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.